Orchard Therapeutics Archives

News and Trends 14 Jul 2021

EMA Market Approval Rate for Small Biotechs Skyrocketed Last Year

The success rate for small biotechs applying for regulatory approval from the EMA has risen by over 100% since 2016, which analysts partly attribute to increased access to sophisticated technology and funding. According to a recent announcement from the EMA, the regulator greenlit a whopping 89% of applications for marketing authorization for new medicines from […]

July 14, 2021 - 3 minutesmins - By Victor Kotsev

Best in Biotech 11 Jan 2021

The 21 European Biotech Companies To Watch in 2021

As we enter 2021, the biotech industry is already bustling with activity. Here’s a list of 21 European biotech companies likely to make a big splash in the biotechnology sector over the next year. There were many memorable moments for the European biotech industry in 2020. The Covid-19 pandemic took over the media and many […]

January 11, 2021 - 11 minutesmins - By Larissa Warneck-Silvestrin

gene therapy cell therapy advanced therapy 4BIO

News and Trends 9 Sep 2019

4BIO Capital Raises €45M Fund to Invest in Advanced Therapies

The London-based life sciences investor 4BIO Capital has raised €45M in the first close of a fund to nurture companies developing advanced therapies such as gene and cell therapies. This is the first closing of 4BIO’s second fund, called 4BIO Ventures II, which is expected to total €136M ($150M) by late 2020. The fund will […]

September 9, 2019 - 3 minutesmins - By Jonathan Smith

News and Trends 5 Sep 2019

Orchard’s Gene Therapy Improves Children’s Motor Ability

Orchard Therapeutics’ gene therapy for metachromatic leukodystrophy (MLD) resulted in motor ability improvements more than six times over the target endpoint, according to data released at a recent symposium. “Metachromatic leukodystrophy is a rare disease that affects the brain,” explained Mark Rothera, CEO of Orchard Therapeutics. “Kids born with MLD lose motor function very fast […]

September 5, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

Expert Advice 7 Aug 2019

Why Making the Jump from Pharma to Biotech Can be a Life Changing Experience

In less than two years, Orchard Therapeutics has changed from a small, relatively unknown UK biotech specializing in gene therapy into a billion euro company listed on the Nasdaq. This is in no small part due to the skills and experience of Mark Rothera, its CEO and President, who joined the company in 2017. Orchard […]

August 7, 2019 - 13 minutesmins - By Helen Albert

News and Trends 30 Apr 2019

Orchard’s Gene Therapy Shows Potential in Treating Patients with Beta Thalassemia

Patients with the life-threatening blood disorder beta-thalassemia required fewer blood transfusions after receiving a gene therapy developed by the UK company Orchard Therapeutics, with four out of nine no longer depending on transfusions. Beta thalassemia is a genetic disorder that affects hemoglobin, a protein that blood cells use to carry oxygen. In the most severe […]

April 30, 2019 - 3 minutesmins - By Jonathan Smith

orchard therapeutics cell therapy stem cell rare disease

News and Trends 28 Mar 2019

Gene Therapy Exceeds Expectations in Treating Children’s Neurological Disease

A gene therapy developed by the UK company Orchard Therapeutics has greatly improved the motor symptoms of children with an incurable neurological disease. The 20 children in the phase II trial suffered from metachromatic leukodystrophy, a rare genetic disease caused by the mutation of a protein that breaks down sulfur-containing molecules in cells. This leads […]

March 28, 2019 - 3 minutesmins - By Jonathan Smith

gene therapy ada scid orchard therapeutics

News and Trends 25 Feb 2019

Orchard Achieves Good Survival with Cell Therapy for Rare Immune Deficiency

All 20 patients with a rare immunodeficiency disease survived for at least two years after receiving a cell therapy developed by Orchard Therapeutics. The patients had a genetic disease called adenosine deaminase–deficient severe combined immune deficiency (ADA-SCID) — also known as bubble boy syndrome. Caused by a mutation on a vital gene, the disease weakens […]

February 25, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 7 Dec 2018

Orchard’s Gene Therapy for Rare Immune Disease Works for Over a Year

A single dose of a gene therapy developed by Orchard Therapeutics can restore immune function for at least a year in patients with X-linked chronic granulomatous disease (X-CGD). The gene therapy was trialed in patients between the ages of 2 and 27 with the rare disease, which is caused by a rare genetic mutation that […]

December 7, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

Orchard therapeutics gene therapy header

News and Trends 1 Nov 2018

Gene Therapy Company’s IPO Shoots it to Billion-Euro Biotech List

Orchard Therapeutics, a British company developing gene therapy for rare genetic diseases, has launched its Nasdaq IPO and is now reportedly worth $1.25B (€1B). This IPO propels Orchard to the handful of European biotechs worth €1B or more. The new money might help with the marketing and manufacture of Strimvelis, an EMA-approved gene therapy for […]

November 1, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 13 Aug 2018

Orchard Therapeutics Raises €132M to Develop Gene Therapies

Orchard Therapeutics raised $150M (€132M) in Series C financing to bring its gene therapies from clinical testing to regulatory approval. The British biotech will use the funding to develop its most advanced clinical programs, which aim to treat rare inherited metabolic and immune system diseases. The news follows Orchard’s acquisition of GSK’s entire gene therapy […]

August 13, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 3 May 2018

FDA Backs Gene Therapy for Fatal Neurodegenerative Childhood Disease

Orchard Therapeutics has received a fourth Rare Pediatric Disease Designation from the FDA for its gene therapy candidate for metachromatic leukodystrophy. Orchard Therapeutics, based in London, has received a Rare Pediatric Disease Designation form the FDA for its gene therapy OTL-200. The treatment is for patients with metachromatic leukodystrophy (MLD), a fatal genetic disease that causes […]

May 3, 2018 - 1 minutemin - By Alexander Burik

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us